CAR-T Meeting 2023 | Combinatorial CAR-T approaches being explored in multiple myeloma
Hermann Einsele, MD, FRCP, University Hospital of Würzburg, Würzburg, Germany, briefly discusses combinatorial CAR-T approaches being explored in multiple myeloma, and comments on how these strategies may be used to overcome mechanisms of resistance and improve CAR-T cell efficacy. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So, combinatorial CAR-T cell approaches are either to combine two CAR-T cell populations targeting different surface antigens that is increasingly used or using so-called dual CARs, which target in one receptor or in two receptors expressed on one cell, two targets on the myeloma cell. And this is something that is already common in lymphoma and especially in ALL, and it’s a strategy to overcome resistance...
So, combinatorial CAR-T cell approaches are either to combine two CAR-T cell populations targeting different surface antigens that is increasingly used or using so-called dual CARs, which target in one receptor or in two receptors expressed on one cell, two targets on the myeloma cell. And this is something that is already common in lymphoma and especially in ALL, and it’s a strategy to overcome resistance. In addition, combinatorial approaches can also be combining a CAR-T cell product with, for example, small molecules. And it has been shown that you can use tyrosine kinase inhibitors, IMiDs, CELMoDs to activate CAR-T cells or to increase their persistence following CAR-T cell infusion. And furthermore, immune checkpoint blockers could also be interesting to really overcome some tumor-intrinsic resistance mechanisms in multiple myeloma.
Read more...
